Genoptix, a NeoGenomics Company
Right Answer, Right Now
Advancing positive outcomes in oncology through innovation, quality and service
Oncology Expertise
For almost 20 years, Genoptix, a NeoGenomics Company, has provided the vital insights cancer care teams need to achieve the best possible outcome for each and every patient. Our broad menu of testing solutions spans from pathology expertise to next-generation testing, enabling confident decisions in optimizing precision medicine. Having diagnosed over 1.7 million patients and counting, Genoptix sets a higher standard of quality, from science to service. Because what matters most is delivering the right answer, right now.
For more details, see http://www.genoptix.com.
For the latest news, visit NeoGenomics Laboratories at https://www.linkedin.com/company/neogenomics-laboratories.
Right Answer, Right Now
Advancing positive outcomes in oncology through innovation, quality and service
Oncology Expertise
For almost 20 years, Genoptix, a NeoGenomics Company, has provided the vital insights cancer care teams need to achieve the best possible outcome for each and every patient. Our broad menu of testing solutions spans from pathology expertise to next-generation testing, enabling confident decisions in optimizing precision medicine. Having diagnosed over 1.7 million patients and counting, Genoptix sets a higher standard of quality, from science to service. Because what matters most is delivering the right answer, right now.
For more details, see http://www.genoptix.com.
For the latest news, visit NeoGenomics Laboratories at https://www.linkedin.com/company/neogenomics-laboratories.
Location: United States, California, Carlsbad
Employees: 201-500
Total raised: $17.3M
Founded date: 1999
Investors 3
| Date | Name | Website |
| - | Bantam Gro... | bantamgrou... |
| - | Chicago Gr... | cgp.com |
| - | Tullis Hea... | tullisfund... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.08.2005 | Series D | $17.3M | - |
Mentions in press and media 7
| Date | Title | Description |
| 03.12.2020 | Slone Partners Places John Leite as Chief Business Officer at InterVenn Biosciences | “John Leite is an experienced and highly accomplished business development and marketing specialist in the biotechnology and diagnostics sectors,” said Slone Partners President Tara Kochis-Stach. SOUTH RIDING, Va. (PRWEB) December 03, 2020 ... |
| 30.10.2018 | Term Sheet — Tuesday, October 30 | CRYPTO FUNDING Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop The fresh infusion of capital will be used to accelerate global expansion and the offering of more cryptocurrencies. A sourc... |
| 08.03.2017 | Term Sheet — Wednesday, March 8 | HEAVY LIFTING Good morning! In today’s guest column, Fortune writer Robert Hackett weighs in on Uber’s terrible, no good, very bad start to 2017—plus discusses one of the biggest cyber deals of the week: CA Technologies’ acquisition of Vera... |
| 07.03.2017 | Ampersand Capital Partners and 1315 Capital to Acquire Genoptix from Novartis | The management team led by Joseph M. Limber, in partnership with Ampersand Capital Partners and 1315 Capital, has completed the acquisition of Genoptix, Inc., a Carlsbad, California-based provider of testing solutions in hematology and soli... |
| 30.01.2017 | Term Sheet — Monday, January 30 | THE WEEKEND The tech industry has found its backbone, making increasingly bold statements and donations in reaction to President Trump’s order to deny entry to refugees and citizens of predominantly Muslim countries over the weekend. It cul... |
| 30.10.2007 | Life sciences briefing: Tuesday, Oct. 30, 2007 | Featured companies: Acceleron Pharma, Bledsoe Brace Systems, Eurobiobiz, Genoptix, Harmony Information Systems, ImmuneWorks, Pasteuria Bioscience, Renal CarePartners, Quantum Genomics, Synergy Software, Vitreo Retinal Technology UPDATED: Ex... |
| 01.08.2007 | Genoptix files $86M IPO for diagnostic services | Genoptix, a Carlsbad, Calif., provider of diagnostic services to cancer and blood-disease specialists, filed to raise as much as $86.25 million in an intial offering. The company specializes in genetic and other testing of blood and bone-ma... |